|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
Nasal delivery has traditionally been restricted to topically acting substances used to treat the common cold and nasal allergies. Recently however, there has been increased interest in the nose as an alternative to oral delivery and injection for many systemic drugs and vaccines. The highly vascularised and immunogenic nasal mucosa offers potential advantages in terms of quick action, improved bio-availability and patient compliance as well as improved immune response for vaccines.
Faced with surging drug development costs and fierce generic competition, pharmaceutical companies are under increasing pressure to find ways to increase and prolong the profitability of both existing and new products. In addition, many of the advanced molecules being developed by biotechnology companies require more efficient delivery than that offered by conventional delivery routes and systems. The challenge of optimising the bio-availability and patient compliance of these expensive molecules are other significant drivers for the development of novel drug delivery systems. If successful, reformulation allied with novel delivery systems provide powerful tools for improving efficiency and differentiating a product from those of competitors.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukaemia
BEERSE, BELGIUM, 10 December 2022 – The Janssen Pharmaceutical
Companies of Johnson & Johnson today announced new four-year
follow-up results from the Phase 3 GLOW study (Abstract #93),1 which showed fixed-duration treatment with IMBRUVICA® (ibrutinib) + venetoclax (I+V) reduced the risk of progression or death
by 79 percent among older and/or unfit patients with previously
untreated chronic lymphocytic leukaemia (CLL) compared to patients
treated with chlorambucil plus obinutuzumab (Clb+O).1 These
results were highlighted in an oral presentation during the 2022
American Society of Hematology (ASH) Annual Meeting, taking place in New
Orleans, U.S.1
More info >> |
|
 |
White Papers |
 |
|
ConsulTech GmbH
ConsulTech GmbH
ConsulTech is a consulting company founded in 1992. Since then, we have
been supporting biotech-nology, pharmaceutical and medical technology
companies as well as research institutions with the entire process of
setting-up and executing proposals for R&D projects. In projects
funded by the European Commission, ConsulTech supports the coordinator
by resuming administrative tasks allow-ing coordinators and partners to
fully concentrate on the scientific and technical success of the
pro-ject. We solve financial and administrative issues, organise
meetings, take care of the timely delivery of milestones and reports and
much more.
More info >> |
|
|
